BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21516739)

  • 1. [Study of bone marrow microvessel density is one of the diagnostic approaches in patients with Ph-negative chronic myeloproliferative diseases].
    Sokolova MA; Khoroshko ND; Tsvetaeva NV; Semenova EA; Kaplanskaia IB; Frank GA; Misiurin AV
    Ter Arkh; 2010; 82(12):47-51. PubMed ID: 21516739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.
    Lekovic D; Gotic M; Skoda R; Beleslin-Cokic B; Milic N; Mitrovic-Ajtic O; Nienhold R; Sefer D; Suboticki T; Buac M; Markovic D; Diklic M; Cokic VP
    Ann Hematol; 2017 Mar; 96(3):393-404. PubMed ID: 27924369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inability of immunomorphometric assessment of angiogenesis to distinguish primary versus secondary myelofibrosis.
    Sharma P; Pati HP; Mishra PC; Dinda AK; Gupta R; Sharma A; Jacob TG
    Anal Quant Cytol Histol; 2011 Aug; 33(4):236-44. PubMed ID: 21980629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders.
    Kvasnicka HM; Thiele J
    Histol Histopathol; 2004 Oct; 19(4):1245-60. PubMed ID: 15375769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
    Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
    Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
    Florena AM; Tripodo C; Iannitto E; Porcasi R; Ingrao S; Franco V
    Haematologica; 2004 Aug; 89(8):911-9. PubMed ID: 15339673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
    Yigit N; Covey S; Barouk-Fox S; Turker T; Geyer JT; Orazi A
    Hum Pathol; 2015 Aug; 46(8):1217-25. PubMed ID: 26093937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
    Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical correlation of bone marrow microvessel density in essential thrombocythemia.
    Panteli K; Zagorianakou N; Agnantis NJ; Bourantas KL; Bai M
    Acta Haematol; 2005; 114(2):99-103. PubMed ID: 16103633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.
    Thiele J; Kvasnicka HM; Fischer R
    Ann Hematol; 1999 Nov; 78(11):495-506. PubMed ID: 10602893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
    Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
    Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.